MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells
- 10 October 2006
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 102 (3) , 253-261
Abstract
Sex steroids play a dominant role in breast carcinogenesis by still largely unknown mechanisms. Matrix metalloproteinases (MMPs) have been extensively studied in the context of matrix biology but it is not known if sex steroids affect MMPs in breast cancer. MMPs degrade extracellular matrix components enabling tumor cell invasion and metastasis, but may also regulate the bioavailability of a variety of biologically active molecules such as anti-angiogenic fragments, which may be beneficial for the host. This study shows that estradiol and tamoxifen regulate MMP-2 and MMP-9 as well as TIMP-1 and TIMP-2 in ER + PR + human breast cancer cells. The main finding was a significant effect of tamoxifen exposure, which increased intracellular and secreted protein levels whereas estradiol induced a significant decrease. The overall net effect of these alterations resulted in increased MMP-2/MMP-9 activity by tamoxifen treatment, which also significantly increased extracellular endostatin levels. We conclude that estradiol and tamoxifen have the ability to modulate MMP-2/MMP-9 activity, and endostatin levels in human breast cancer in vitro. The results suggest a possible role of MMP modulation associated with a generation of anti-angiogenic fragments in the therapeutic effect of tamoxifen in breast cancer.Keywords
This publication has 40 references indexed in Scilit:
- Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinomaBreast Cancer Research and Treatment, 2004
- Regulation of matrix biology by matrix metalloproteinasesCurrent Opinion in Cell Biology, 2004
- Regulation of angiogenesis by extracellular matrixBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2004
- Inhibition of transforming growth factor-beta and matrix metalloproteinases by estrogen and prolactin in breast cancer cellsCancer Letters, 2004
- Estradiol increases extracellular levels of vascular endothelial growth factor in vivo in murine mammary cancerInternational Journal of Cancer, 2003
- Physiological levels of tumstatin, a fragment of collagen IV α3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via αVβ3 integrinCancer Cell, 2003
- Inflammation and cancerNature, 2002
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancerThe Lancet, 1997